Takeda’s Zasocitinib Delivers Strong Phase 3 Wins in Plaque Psoriasis

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psor...

December 19, 2025 | Friday | News
Inhibrx Advances INBRX-106 and Ozekibart Programs, Expands Clinical Momentum Across Solid Tumors

Inhibrx Biosciences, Inc. a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology announced an update on the INBR...

December 18, 2025 | Thursday | News
Norgine Secures Exclusive Rights to Vir Biotechnology’s Hepatitis Delta Combination Therapy

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceutical...

December 18, 2025 | Thursday | News
Affibody Advances HER2 Radioligand Therapy ABY-271 to Next Phase of Clinical Study

Affibody AB announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) cand...

December 17, 2025 | Wednesday | News
Allink Biotherapeutics Secures $47M to Accelerate Next-Generation ADC and Multispecific Antibody Pipeline

The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with stron...

December 17, 2025 | Wednesday | News
Neupulse Launches Drug-Free Wearable Offering New Hope for People Living With Tourette Syndrome

Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people l...

December 17, 2025 | Wednesday | News
Lindus Health and Quotient Sciences Form Strategic Partnership to Accelerate Early-Phase Clinical Development

Lindus Health, the "anti-CRO" running radically faster, more  reliable clinical trials for life science pioneers, and Quotient Sciences, a leading g...

December 17, 2025 | Wednesday | News
Minghui Pharma Secures FDA IND Clearance to Launch Global Phase 3 Trials of MHB018A in Thyroid Eye Disease

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announc...

December 16, 2025 | Tuesday | News
RedHill Biopharma Highlights Opaganib as Potential Add-On Therapy for Venetoclax-Resistant CLL

Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CL...

December 16, 2025 | Tuesday | News
Greenwich LifeSciences Reports ~80% Reduction in Breast Cancer Recurrence in Phase III FLAMINGO-01 Non-HLA-A*02 Arm

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO...

December 16, 2025 | Tuesday | News
Vaxxas Gains Regulatory Green Light to Manufacture HD-MAP for Clinical Trials

Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration (TGA) to manufacture the Company&rsqu...

December 16, 2025 | Tuesday | News
InnoCare’s Orelabrutinib Meets Primary Endpoint in Phase IIb SLE Study, Advances to Phase III

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced th...

December 15, 2025 | Monday | News
Anova Launches Free AI-Powered Patient Matching Platform to Accelerate Clinical Trial Enrollment

Anova launches a free AI-enabled patient matching solution that uses proprietary algorithms to connect patients to 200,000+ open clinical trials with...

December 15, 2025 | Monday | News
Savara Secures Key European Patent for MOLBREEVI as It Prepares Global Regulatory Filings

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the EPO notified the...

December 12, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close